Navigation Links
China Cord Blood Corporation Reports Financial Results for the First Quarter of Fiscal 2012
Date:8/29/2011

generated from processing fees increased to RMB64.9 million ($10.0 million) from RMB56.7 million in the prior year period, reflecting 12,828 new subscriber sign-ups this quarter, a 5.3% increase in new subscribers from the prior year period, as well as the effect of the processing fee increase.

Revenue generated from storage fees increased to RMB22.6 million ($3.5 million) from RMB15.0 million, which accounted for 25.8% of the total first quarter revenue as compared to 20.9% in the prior year period. The Company's accumulated subscriber base grew 40.4% year-over-year to 198,658, backed by continued strong demand from the Beijing and Guangdong markets.

GROSS PROFIT. Gross profit in the first quarter increased by 24.1% to RMB67.6 million ($10.5 million) from RMB54.4 million in the prior year period. Gross margin reached 77.3%, primarily reflecting greater revenue contribution from higher margin storage fees.  

OPERATING INCOME. Operating income for the first quarter increased 31.7% to RMB30.8 million ($4.8 million) from RMB23.4 million in the prior year period, driven by economies of scale, successful cost control measures, and the sustained subscriber base growth. Operating margin rose 260 basis points to 35.2% from 32.6% in the prior year period. Depreciation and amortization expenses for the first quarter were RMB7.1 million ($1.1 million).

Research and Development Expenses. Research and development expenses were RMB1.8 million ($0.3 million), compared to RMB1.5 million in the prior year period.

Sales and Marketing Expenses. Sales and marketing expenses increased by 24.9% to RMB12.6 million ($2.0 million) from RMB10.1 million from the prior year period as the Company continued to roll-out marketing and promotional activities in the Beijing Municipality and Gu
'/>"/>

SOURCE China Cord Blood Corporation
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10

Related biology technology :

1. China Cord Blood Corporation to Report First Quarter Fiscal 2012 Financial Results
2. Industrial Biotechnology China News 1106
3. China Agri-Business Acquired Management and Operation Rights of Shaanxi Qinfeng Agrochemical Inc. in Xian, China
4. China-Biotics, Inc. Receives NASDAQ Delisting Notification
5. China-Biotics Provides Update
6. China Cord Blood Corporation Reports Financial Results for the Fourth Quarter and Full Year of Fiscal 2011
7. Reportlinker Adds Industrial Biotechnology China News 1105 - Annual Subscription
8. NIST contests in China put next-gen robot technologies to the test
9. Reportlinker Adds Future of White Biotechnology in China
10. China Cord Blood Corporation to Report Fourth Quarter and Full Year Fiscal 2011 Financial Results
11. MicroConstants China Receives Endorsement of OECD GLP Compliance
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/17/2014)... , Dec. 17, 2014   Synageva BioPharma ... company developing therapeutic products for rare disorders, announced today ... being held in San Francisco, CA. ... and Chief Executive Officer, will present on Monday, January ... The presentation will be webcast live and may be ...
(Date:12/15/2014)... 2014 Organovo Holdings, Inc. (NYSE MKT: ... delivering breakthrough 3D bioprinting technology,  today celebrated continued ... its exVive3D TM Human Liver Tissue.  The ... commercial release on November 18, has been recognized ... awards for innovation. Most recently, on ...
(Date:12/15/2014)... Dec. 15, 2014  Ascendis Pharma A/S, a ... to address significant unmet medical needs, today announced ... 2 pediatric study to evaluate once-weekly TransCon Growth ... GHD.  This interim analysis consists of 25 patients, ... in the study, completing all six months of ...
(Date:12/13/2014)... 12, 2014 Clarassance, a privately held ... new name: Therabron Therapeutics , Inc. The new ... (a type of structure in the lungs similar to ... to develop novel protein therapeutics for the treatment of ... to change the name to mark the company's escalation ...
Breaking Biology Technology:Organovo Celebrates a Positive 2014 Reception of its exVive3DTM Human Liver Tissue Product 2Organovo Celebrates a Positive 2014 Reception of its exVive3DTM Human Liver Tissue Product 3Ascendis Pharma A/S Announces Positive Six-Month Interim Results from a Phase 2 Pediatric Study of Once-Weekly TransCon Growth Hormone for the Treatment of Growth Hormone Deficiency 2Ascendis Pharma A/S Announces Positive Six-Month Interim Results from a Phase 2 Pediatric Study of Once-Weekly TransCon Growth Hormone for the Treatment of Growth Hormone Deficiency 3Ascendis Pharma A/S Announces Positive Six-Month Interim Results from a Phase 2 Pediatric Study of Once-Weekly TransCon Growth Hormone for the Treatment of Growth Hormone Deficiency 4Maryland-based Biotech Company's Path Forward in Treating Respiratory Diseases Sparks Name Change 2
... The 2nd Aesthetic Plastic Surgery and Anti Aging Medicine: The ... in New York on June 10-12, 2011. This three day ... medicine, the science of stem cells, and fat grafting applications ... plastic surgeons Drs. Sydney Coleman and J. Peter Rubin, among ...
... American Regent is conducting a nationwide voluntary recall ... mL Single Dose VialsNDC # 0517-4901-25;andDexamethasone Sodium Phosphate Injection, ... Sodium Phosphate Injection, 4 mg/mL, 30 mL Multiple Dose ... voluntary recall, initiated on March 16, 2011 to the ...
... NEW YORK, March 16, 2011 Reportlinker.com announces ... in its catalogue: Global Specialty ... This report analyzes the worldwide markets ... following product segments - Specialty Medical Enzymes, Polymerases, ...
Cached Biology Technology:Aesthetic Plastic Surgery and Anti Aging Medicine Symposium Features New Developments in the Science of Stem Cells and Fat Grafting 2American Regent Initiates Voluntary Nationwide Recall of Dexamethasone Sodium Phosphate Injection, USP, 4 mg/mL, 1 mL Single Dose Vials; 5 mL and 30 mL Multiple Dose Vials 2American Regent Initiates Voluntary Nationwide Recall of Dexamethasone Sodium Phosphate Injection, USP, 4 mg/mL, 1 mL Single Dose Vials; 5 mL and 30 mL Multiple Dose Vials 3American Regent Initiates Voluntary Nationwide Recall of Dexamethasone Sodium Phosphate Injection, USP, 4 mg/mL, 1 mL Single Dose Vials; 5 mL and 30 mL Multiple Dose Vials 4American Regent Initiates Voluntary Nationwide Recall of Dexamethasone Sodium Phosphate Injection, USP, 4 mg/mL, 1 mL Single Dose Vials; 5 mL and 30 mL Multiple Dose Vials 5Global Specialty Enzymes Industry 2Global Specialty Enzymes Industry 3Global Specialty Enzymes Industry 4Global Specialty Enzymes Industry 5Global Specialty Enzymes Industry 6Global Specialty Enzymes Industry 7Global Specialty Enzymes Industry 8Global Specialty Enzymes Industry 9Global Specialty Enzymes Industry 10Global Specialty Enzymes Industry 11Global Specialty Enzymes Industry 12Global Specialty Enzymes Industry 13Global Specialty Enzymes Industry 14Global Specialty Enzymes Industry 15Global Specialty Enzymes Industry 16Global Specialty Enzymes Industry 17Global Specialty Enzymes Industry 18Global Specialty Enzymes Industry 19Global Specialty Enzymes Industry 20Global Specialty Enzymes Industry 21Global Specialty Enzymes Industry 22Global Specialty Enzymes Industry 23Global Specialty Enzymes Industry 24
(Date:12/10/2014)... --Research and Markets ( http://www.researchandmarkets.com/research/xclcvw/biometrics_market ) ... Market in Japan 2014-2018" report to their ... The integration of biometrics and smart ... upgradation of the driver,s license is one of ... the aforementioned projects, biometrics is being used as ...
(Date:12/4/2014)... , Dec. 3, 2014  Crossmatch™, a ... announced that its DigitalPersona ® Pro Enterprise ... have been deployed throughout First Bank branch locations ... South Carolina and Virginia. First Bank, ... Southern Pines, North Carolina , selected ...
(Date:11/21/2014)... -- Earlier this year Donald Spector , Chairman of ... the most prolific inventors in the world, got a ... to third party agencies. Spector envisioned this technology even ... earliest known patents in this area. Now major technology ... care, elder care and hospital applications. This technology has ...
Breaking Biology News(10 mins):Biometrics Market in Japan 2014-2018: Key Vendors are DDS, Fujitsu, Hitachi and NEC 2First Bank Partners with Crossmatch to Increase Log In Security 2First Bank Partners with Crossmatch to Increase Log In Security 3Patented Biosensor Wearable Technology Provides a More Civilized Method of Quarantine 2Patented Biosensor Wearable Technology Provides a More Civilized Method of Quarantine 3Patented Biosensor Wearable Technology Provides a More Civilized Method of Quarantine 4
... inferences about the intentions of other individuals in order ... of everyday life that we humans take for granted. ... Max Planck Institute in Germany, this ability is present ... in the April issue of Current Directions in Psychological ...
... the National Institute on Drug Abuse (NIDA), part of ... time identified genes that might increase a person’s ability ... by Dr. George Uhl at NIDA’s Intramural Research Program ... the Center for Nicotine and Smoking Cessation Research at ...
... international team of 19 researchers calls for better forecasting ... The researchers, led by Daniel B. Botkin, note that ... be at risk from global warming, surprisingly few species ... period encompassing several ice ages. They suggest that this ...
Cached Biology News:Man's best friend lends insight into human evolution 2NIDA study identifies genes that might help some people abstain from smoking 2
Mouse monoclonal [34B12] to Nop5p + Nop58p - Nucleolar Marker ( Abpromise for all tested applications)....
... Nop1p/Fibrillarin was originally identified ... yeast, Saccharomyces cerevisiae (accession P15646). The ... viability and is localized in the ... is fibrillarin (accession P22087) a component ...
... Protein A and Protein G bind specifically ... Protein A and Protein G conjugates are ... immunoglobulins (antibodies) and immunoglobulin subtypes from serum, ... other biological fluids. These reagents are also ...
... G bind specifically to Fc regions of ... G conjugates are commonly used as affinity ... subtypes from serum, hybridoma ascites fluids, tissue ... reagents are also commonly used to capture ...
Biology Products: